MET and non-small cell lung carcinoma: In this respect, EGFRm+ NSCLC patients with MET amplification have probably a minor propensity to metastasize to the central nervous system (CNS); thus, combinations of MET inhibitors with EGFR-TKIs that are less CNS penetrable than Osimertinib are being investigated too [11,96].